GlassScriptPhysician profile
Analyn Holman
NPI 1972041390
$2,673.12
in general payments reported to CMS, 2019-2025
25 companies · $903 in 2025
The $903 reported for 2025 was more than what 86% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $174 · 2022: $723 · 2023: $451 · 2024: $423 · 2025: $903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,776.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $635.02 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $384.91 | 2022-2025 | Verquvo |
| Abbott Laboratories | $227.78 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $200.90 | 2021-2025 | Optimizer |
| Sanofi-Aventis U.S. LLC | $175.54 | 2022-2023 | |
| Medtronic, INC. | $154.95 | 2025 | Symplicity G3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.21 | 2024-2025 | Jardiance |
| Amgen INC. | $138.03 | 2021-2025 | Repatha |
| Pfizer INC. | $107.91 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $55.75 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $51.40 | 2021-2022 | |
| W. L. Gore & Associates, INC. | $49.05 | 2025 | Excluder Conformable Aaa Endoprosthesis With Active Control |
| Alnylam Pharmaceuticals INC. | $47.87 | 2022-2023 | Amvuttra |
| Baxter Healthcare | $38.83 | 2022 | |
| Edwards Lifesciences Corporation | $36.64 | 2025 | Sapien 3 Ultra Resilia |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $34.93 | 2023 | Arcalyst |
| Altathera Pharmaceuticals LLC | $31.36 | 2024-2025 | Sotalol Hydrochloride |
| Novo Nordisk INC | $29.11 | 2021-2024 | Ozempic |
| Actelion Pharmaceuticals US, INC. | $24.45 | 2023 | Opsumit, Uptravi |
| Arbor Pharmaceuticals, INC. | $23.14 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $18.92 | 2025 | Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $15.93 | 2025 | |
| Bridgebio Pharma, INC. | $15.88 | 2025 | Attruby |
| Lexicon Pharmaceuticals, INC. | $15.84 | 2023 | Inpefa |
| Abiomed | $15.77 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Analyn Holman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.